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httpcense.Abstract Background: Rational prescription of antibiotics in acute exacerbations of COPD
(AECOPD) requires predictive markers. Acute phase reactants are capable of demonstrating the
inﬂammation; however, they cannot be employed to make a difference between bacterial and non-
bacterial causes of the inﬂammation. Recently, measurement of procalcitonin (PCT) levels appears
to be useful in order to minimize this problem. We aimed to evaluate the diagnostic and prognostic
role of procalcitonin in (AECOPD).
Patients and methods: A total of 50 patients with AECOPD and 10 of apparently healthy indi-
viduals (control group) were studied. On presentation, serum PCT concentrations were measured,
and quantitative sputum culture was performed for AECOPD. The patients were reevaluated when
they had returned to their stable clinical state. Pathogenic bacterial microorganism (PBM) was only
regarded as signiﬁcant if they reached a growth 105 CFU/ml, indicating the presence of bacterial
exacerbation of COPD. The patients were classiﬁed into two subgroups: group A included patients
with bacterial AECOPD (n= 20), group B included patients with nonbacterial AECOPD (n= 30).
Results: On presentation, the levels of PCT for patients of group A (2.69 ± 0.62 ng/mL) were
signiﬁcantly higher than group B (0.07 ± 0.02 ng/mL) and control group (0.05 ± 0.02 ng/mL)
(p< 0.001). When they had returned to their stable state, the levels of PCT for patients of group
A decreased to (0.06 ± 0.03 ng/mL), which was signiﬁcantly lower than that in exacerbation
(2.69 ± 0.62 ng/mL) (p< 0.001); But in patients of group B compared with exacerbation the levelsail.com (K.H. Mohamed).
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302 K.H. Mohamed et al.of PCT did not changed (0.068 ± 0.02 ng/mL) (p> 0.05). In the stable state, there were no differ-
ences in the PCT measurement between the two subgroups as well as between patients and control.
Furthermore, a signiﬁcant correlation was recorded between PCT levels in group A at time of pre-
sentation and temperature (r= 0.898, p< 0.05), leucocytic count (r= 0.889, p< 0.05), FEV1%
of predicted (r= 0.898,p< 0.05), ESR (r= 0.899, p< 0.05), CRP (r= 0.895, p< 0.05) and
duration of hospital stay (r= 0.897, p< 0.05).
Conclusions: Procalcitonin is a good marker for differentiation between bacterial and nonbacte-
rial AECOPD and could be used to guide antibiotic therapy and reduce antibiotic overuse in hos-
pitalized patients with AECOPD.
ª 2012 The Egyptian Society of Chest Diseases and Tuberculosis. Production and hosting by Elsevier B.V.
Open access under CC BY-NC-ND license.Introduction
COPD constitutes a major health problem [1]. Acute exacerba-
tions of COPD (AECOPD) have considerable impact on mor-
bidity, mortality and quality of life [2]. Common triggers for
AECOPD include viral and/or bacterial infection of the tra-
cheobronchial tree and air pollution, but the cause of approx-
imately one-third of severe exacerbations cannot be identiﬁed
[3]. Whereas patients with signs of bacterial infection and more
severe exacerbations seem to beneﬁt from antibiotics, prescrib-
ing antibiotics for viral infections or noninfectious causes of
AECOPD is ineffective and increases the risk of toxicity and
the development of bacterial resistance [4,5]. In patients with
COPD, the clinical manifestations of systemic inﬂammation
due to infectious and non-infectious causes are similar. The
differential diagnosis of these two conditions is very important
in order to administer the correct treatment regimen and avoid
unnecessary antibiotic use, thus reducing the morbidity, mor-
tality and care-related costs. The decision to use antibiotics
and selection of the type of antibiotic may be difﬁcult in a sig-
niﬁcant number of cases, primarily due to the challenges
encountered in conﬁrming the diagnosis of bacterial infections.
Classical diagnostic parameters including CRP and leukocyte
count do not have sufﬁcient speciﬁcity in differentiating be-
tween bacterial infections, non-infectious systemic inﬂamma-
tions or viral infections. Therefore, more speciﬁc and reliable
markers that might be helpful in deciding the treatment are
needed in these patients [6]. Nevertheless, antibiotic use in AE-
COPD is undoubtedly still excessive, exposing patients to con-
siderable cost and potential adverse effects, and driving
antibiotic resistance. In this context, a rapid, speciﬁc test to
identify lower respiratory bacterial infections would be a major
advancement, limiting the inappropriate use of antibiotics
which is considered to be a main cause of the spread of antibi-
otic-resistant bacteria [7]. Serum procalcitonin levels are sug-
gested to be one of the biomarkers for predicting a bacterial
infection [8]. Procalcitonin (PCT) is a protein having a molec-
ular weight of 13 kDa and it consists of 116 amino acid resi-
dues The exact regions of its secretion are not yet clear [9].
Some literature suggests that PCT is secreted from neuroendo-
crine cells of the liver, small intestine and thyroid cells. In
healthy humans, its normal serum level is 0.1 ng/mL. In a pre-
vious study, administration of bacterial endotoxin to healthy
individuals resulted in an increase in PCT levels starting two
hours after administration, with a peak value reached in 12 h
[10]. Consequently, the serum level remains constant for an-
other 12 h and decreases back to normal level in 20–24 h.PCT gives rapid response to bacterial infections [11]. Studies
performed in patients with pneumonia revealed that serum
PCT levels have high sensitivity and speciﬁcity in showing
the inﬂammatory response caused by pneumonia [12]. It has
also been suggested in some studies that serum PCT levels
might have a relatively higher sensitivity and speciﬁcity in dif-
ferentiating pneumonias of bacterial origin from those of viral
origin [13]. The aim of this study was to investigate whether the
measurement of PCT can be used in the differentiation of bac-
terial and non-bacterial infection causes of COPD exacerba-
tion, thus helping in planning the treatment.
Patients and methods
Patients
Fifty COPD patients (37 males and 13 females) admitted to the
medical ward due to exacerbation between April 2010 and
June 2011were included in this prospective study after giving
written informed consent. Exclusion criteria included presence
of inﬁltrates on chest radiographs taken at admission and sus-
pected of pneumonia, receiving antibiotics before admission or
presence of other chronic pulmonary diseases.
Deﬁnition
The diagnosis of COPD was based on clinical history, phys-
ical examination ﬁndings, and spirometric criteria according
to the Global Initiative for Chronic Obstructive Lung Dis-
ease (GOLD) guidelines [14]. An exacerbation of COPD
was deﬁned as ‘‘a sustained worsening of the patient’s con-
dition, from the stable state and beyond normal day-to-day
variations, that is acute in onset and necessitates a change
in regular medication in a patient with underlying COPD
[15].
Methods
- Complete medical history.
- General and local chest examination.
- Chest radiography.
- Spirometry was performed according to American Thoracic
society Guidelines.
- Routine blood tests (including CBC, ESR and CRP).
- Blood cultures, sputum culture, and Gram stain (Sputum
was induced with hypertonic saline if subjects were unable
to expectorate an adequate sputum sample spontaneously).
00.5
1
1.5
2
2.5
3
Group A Group B control
(PCT) P < 0.001 2.69 0.07 0.05
(PCT) P < 0.001 
Figure 1 Furthermore; a signiﬁcant correlation was recorded
between PCT levels in group A at time of presentation and
FEV1% of predicted (r= 0.898, p< 0.05), leucocytic count
(r= 0.889, p< 0.05), duration of hospital stay (r= 0.897,
p< 0.05), body temperature (r= 0.898, p< 0.05), CRP
(r= 0.895, p< 0.05) and ESR (r= 0.899, p< 0.05) and Table 3.
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criteria of >25 polymorphonuclear leukocytes and <10
epithelial cells per high power ﬁeld [16].
- A serological diagnostic for antibodies to legionella pneu-
mophila was also performed by indirect immunoﬂuores-
cence, associated with a detection of Legionella
pneumophila serogroup 1 antigen in urine samples.
- Chlamydia pneumoniae and Mycoplasma pneumoniae
were also detected by PCR assay.
Measurement of serum procalcitonin
All blood samples were centrifuged, decanted, aliquoted, and
frozen at 80 C until analyzed at the end of the study period.
PCT was measured using a sensitive immunoassay (KryptorTable 1 Demographic characteristics of the groups.
(A) Bacterial COPD
exacerbation (n= 20)
Age (year) 62 ± 4.2
Sex (M/F) 15/5
Smoking history (n/
pack-year)
18/38 ± 6
FVC (%) 82 ± 3.7
FEV1 (%) 52 ± 10.4
FEV1/FVC 62 ± 6.3
The levels of PCT for patients of group A (2.69 ± 0.62 ng/mL) were sign
(0.05 ± 0.02 ng/mL) (p< .001) Table 2 and Fig. 1.
Table 2 Initial infection parameters in the study and control group
(A) Bacterial COPD
exacerbation (n= 20)
PCT (ng/mL) *2.69 ± 0.62
White blood cell (mm3) *12500 ± 4500
CRP *71.4
ESR (mm/h) *48 ± 17
Duration of hospital
stay (day)
*7 ± 2.3
* p< 0.001 statistically signiﬁcant.PCT, Brahms, Hennigsdorf, Germany) with a functional assay
sensitivity of 0.06 ng/mL, about fourfold above the mean nor-
mal levels [17].
Statistical analysis
All analyses were performed using computer software (SPSS,
version 10.0; SPSS, Inc; Chicago, IL). Data are presented as
mean ± SD unless stated otherwise. Correlations between
PCT and other values were examined with Spearman rank cor-
relation. Statistical signiﬁcance was accepted for a p-value of
<0.05 (see Fig. 1).
Results
The mean age of the patients with bacterial COPD exacerba-
tion (group A) was 62 ± 4.2 years, and included 5 females
and 15 males. The mean age of the patients with non-bacterial
COPD exacerbation (group B) was 66.3 ± 10.5 and included 8
females and 22 males and the mean age of the control group
was 56.3 ± 11.5 and included 2 females and 8 males. Demo-
graphic characteristics of the patient and control groups are
shown in Table 1 (See Table 2).
Discussion
Serum procalcitonin levels are suggested to be one of the bio-
markers for predicting a bacterial infection [8]. In this study,
we have demonstrated that The levels of PCT for patients of
group A with bacterial COPD exacerbation were signiﬁcantly
higher than group B with non-bacterial COPD exacerbation
and control group (p<001). Chang et al. [18] showed that pa-
tients admitted with COPD exacerbation and positive sputum
cultures for bacterial pathogen had signiﬁcantly higher PCT(B) Non-bacterial COPD
exacerbation (n= 30)
Control
(n= 10)
66.3 ± 10.5 56.3 ± 11.5
22/8 8/2
24/42 ± 11 6/28 ± 6
84 ± 4.7 88 ± 4.7
54 ± 8.4 88 ± 10.4
64 ± 6.1 85 ± 5.1
iﬁcantly higher than group B (0.07 ± 0.02 ng/mL) and control group
s.
(B) Non-bacterial COPD
exacerbation (n= 30)
Control
(n= 10)
0.07 ± 0.02 0.05 ± 0.02
6500 ± 2600 6400 ± 2400
22.7 3.4
16 ± 3.6 8 ± 2.6
4 ± 1.3
Table 4 Procalcitonine level at exacerbation and stable states in bacterial and non bacterial groups.
Patient group group A group B
Procalcitonine
level(ng/mL)
Initial value Stable state signiﬁcance Initial value Stable state signiﬁcance
2.69 ± 0.62 ng/mL 0.06 ± 0.03 ng/mL p< .001 0.07 ± 0.02 ng/mL 0.068 ± 0.02 ng/mL P> 0.05
Table 3 Correlation between clinical and laboratory ﬁndings in group A.
Parameters in group A Correlation with r P
PCT FEV1 0.898 p<0.05
PCT White blood cell 0.889 p<0.05
PCT Duration of hospital stay 0.897 p<0.05
PCT Body temperature 0.898 p<0.05
PCT CRP 0.895 p<0.05
PCT ESR 0.899 p<0.05
When they had returned to their stable state, the levels of PCT for patients of group (A) decreased to (0.06 ± 0.03 ng/mL), which was
signiﬁcantly lower than that in exacerbation (2.69 ± 0.62 ng/mL) (p< .001); But in patients of group (B) compared with exacerbation the levels
of PCT did not changed (0.068 ± 0.02 ng/mL).
304 K.H. Mohamed et al.values. A similar result was found in our study. Also other
study showed that the level of circulating procalcitonin is in-
creased in severe bacterial infections, but remains fairly low
in viral infection and non speciﬁc inﬂammatory diseases [9].
The sensitivity and speciﬁcity of PCT in bacterial infections
were found to be 92.6% and 97.5%, respectively [19]. Serum
PCT level above 0.5 ng/mL indicates bacterial infections,
whereas levels above 2 ng/mL show sepsis [10]. When the
threshold level of PCT indicative of bacterial infection was ac-
cepted as 0.5 ng/mL, the positive and negative predictive val-
ues were found to be 100% and 87%, respectively [19]. We
found that PCT has a signiﬁcant correlation with both ESR,
CRP, leucocytic count and body temperature, suggesting that
when these parameters are used in combination with the PCT
increases the predictive value in identifying bacterial infection.
A signiﬁcant correlation was found between the PCT level and
the duration of hospital stay and FEV1 in COPD exacerba-
tions of bacterial etiology in our study, indicating that high
PCT may point to increasing severity of AECOPD. The level
of circulating procalcitonin is increased in severe bacterial
infections. Since the extent and severity of infection gradually
increase in bacterial infections, serum PCT levels have also
been shown to increase [9]. In previous study A signiﬁcant cor-
relation was established between serum procalcitonin (PCT)
levels and duration of hospital stay, ESR and sputum puru-
lence (P= 0.002, P= 0.007, respectively). But there was no
signiﬁcant correlation between serum PCT levels and white
blood cell count and. They concluded that serum PCT mea-
surements would be effective in guiding the treatment in pa-
tients with acute exacerbations of COPD [6]. When they had
returned to their stable state, the levels of PCT for patients
of group A, were signiﬁcantly lower than that in exacerbation.
This agree with a recent study, included nineteen patients with
acute exacerbation of COPD and 16 patients with stable
COPD as the control group, the investigators found that the
mean serum PCT levels in COPD patients with exacerbations
was 1.8 ng/mL and in stable COPD patients was 0.2 ng/mL [6]
(see Table 3).Our ﬁndings suggest that, serum PCT levels have high sen-
sitivity and speciﬁcity in displaying the inﬂammatory response
in patients admitted with COPD exacerbation. In the stable
COPD patients, serum PCT levels were found to be within
normal limits. These ﬁndings agree with previous studies
[20,21]. In conclusion: our study demonstrates that procalcito-
nin is a good marker for differentiation between bacterial and
nonbacterial AECOPD and could be used to guide initiation
and assessing response to antibiotic therapy in patients with
COPD exacerbations suggesting that the use of procalcito-
nin-guided antibiotic therapy has the potential to decrease
unnecessary antibiotic use in nonbacterial COPD exacerba-
tions, thereby decreasing the spread of antibiotic-resistant bac-
teria and reducing antibiotic-related adverse reactions (see
Table 4).
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